Clinical Trial Search

Phase 3 N=42 Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

Gaucher Disease Type 1

Primary: Liver Volume at Baseline and at End of Treatment — 1774.6; 1727.1 cm^3

Actelion Results May 2012 11.9% serious AE View details

Phase 3 N=474 Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Rhinitis, Allergic, Perennial

Primary: Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period — -2.5; -1.6 units on a scale — p=<0.001

Teva Branded Pharmaceutical Products R&D, Inc. Results May 2012 0.2% serious AE View details

Phase 3 N=1,352 Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Infections, Meningococcal

Primary: Serum Bactericidal Assay (Performed Using Baby Rabbit Complement) for Neisseria Meningitidis Serogroups A, C, W-135 and Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and…

GlaxoSmithKline Results May 2012 0.6% serious AE View details

Phase 3 N=31 A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

Hypogonadism

Primary: Number of Participants Who Met Both Index 1 and Index 2 — 23 participants

Merck KGaA, Darmstadt, Germany Results May 2012 0.0% serious AE View details

Phase 3 N=611 Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Infections, Meningococcal

Primary: Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers…

GlaxoSmithKline Results May 2012 0.8% serious AE View details

Phase 3 N=296 Aripiprazole in Children and Adolescents With Bipolar I Disorder

Bipolar Disorder

Primary: Change in Young Mania Rating Scale (Y-MRS) Total Score at Week 4 — -14.04; -16.16; -8.67 points — p=<0.0001

Otsuka Pharmaceutical Development &… Results May 2012 6.1% serious AE View details

Phase 3 N=47 The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

Pneumonia, Bacterial

Primary: Response Rate (Clinical Response, Data Review Committee Assessment) — 97.4; 94.6; 94.4 percentage of participants

Pfizer Results May 2012 2.1% serious AE View details

Phase 3 N=170 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

Cerebrovascular Accident

Primary: Change From Baseline at Week 6 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) — -0.56; -1.21 scores on a scale — p=<0.001

GlaxoSmithKline Results May 2012 1.8% serious AE View details

Phase 3 N=724 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

Influenza

Primary: Serum Haemagglutination-Inhibition (HI) Antibody Titers Against the 3 Vaccine Strains — 14.1; 13.4; 108.4; 108.7 Titer

GlaxoSmithKline Results May 2012 0.3% serious AE View details

Phase 3 N=1,286 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Breast Neoplasms

Primary: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as…

Novartis Pharmaceuticals Results May 2012 19.8% serious AE View details

Phase 3 N=805 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Hepatitis C, Chronic

Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 32; 97 participants — p=0.0202

GlaxoSmithKline Results May 2012 11.3% serious AE View details

Phase 3 N=474 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

HIV Infections

Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.873; 4.840; 4.886 log10 copies/milliliter(log10 copies/mL)

ViiV Healthcare Results May 2012 12.3% serious AE View details

Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation

Anemia

Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05

Indonesia University Results May 2012 0.0% serious AE View details

Phase 3 N=388 Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

Schizophrenia

Primary: Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42 — -33.4; -35.9 scores on a scale

AstraZeneca Results May 2012 0.5% serious AE View details

Phase 3 N=459 A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy

Primary: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12…

Johnson & Johnson Pharmaceutical Research &… Results May 2012 3.6% serious AE View details